泽菲联合盖诺治疗不能耐受顺铂的中晚期非小细胞肺癌临床观察

目的评价泽菲联合盖诺治疗不能耐受顺铂的中晚期非小细胞肺癌的疗效和毒性反应。方法74例中晚期非小细胞肺癌既往均未曾放疗或化疗。PS评分≤3分,生存期超过3个月,随机分为GN组25例（泽菲联合盖诺）,NP组24例（盖诺加顺铂）,GP组25例（泽菲加顺铂）。结果GN组、NP组和GP组有效率分别为44.0%、37.5%和44.0%,差异无显著性（P〉0.05）。GN组与另两组在Ⅲ、Ⅳ度血液学毒性方面比较差异无显著性（P〉0.05）,GN组非血液学毒性比较少（P〈0.05）。结论GN方案疗效较好且毒性较低,故尤其适合于不能耐受顺铂的晚期非小细胞肺癌患者。

Gemcitabine plus vinorelbine for treatment of patients with advanced non-small cell lung cancer who were unendurable to cisplatin-based chemotherapy

Objective To evaluate the efficacy and toxicity of gemcitabine plus vinorelbine in the treatment of patients with advanced non-small cell cancer who were unendurable to cisplatin-based chemotherapy. Methods Seventy-four cases with advanced non-small cell lung cancer （NSCLC） staging Ⅲ and IV ,with PS score 〈 3 points and survival time longer than three months, were divided into three groups. All patients had not been treated previously with radiotherapy and chemotherapy. Twenty-five of these patients were treated with gemcitabine plus vinorelbine （GN group）, 24 cases with vinorelbine plus cisplatin （NP group）, and 25 with gemcitabine plus cisplatin （ GP group）. Results The response rates （RR） were 44. 0% in GN group,37.5 % in NP group,and 44. 0% in GP group. There was no significant difference in RR a- mong the three groups（ P 〉0. 05 ）. There was no significant difference in hematological toxicity of Ⅲ-IV degree between GN group and other two groups （ P 〉 0. 05 ）, while less non-haematological toxicity was seen in GN group （P 〈 0. 05）. Conclusion Gemcitabine plus vinorelbine is a good regimen with low toxicity. It may be suitable for the treatment of patients with advanced NSCLC who were unendurable to cisplatin-based chemotherapy.